{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 34,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/28",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.1,
        "x": 0.88,
        "y": 0.0045
      },
      "kind": "callout",
      "text": "Signal of improvement: Cohen's d* (Symbol Coding): 20 mg: 0.79, 40 mg: 0.56, 80 mg: 0.38",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5efbfecd-fa4d-456d-80e4-b89d2a252411",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.0018
      },
      "kind": "chart",
      "text": "PHASE 2a TRIAL - EFFICACY DATA ON COMPONENTS MCCB COMPOSITE",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a80a3d35-fec3-4784-bf80-d908ed120eaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.0055
      },
      "kind": "list",
      "text": "1. Study demonstrated dose-related trends for improvements on each MCCB neurocognitive endpoints... 2. Symbol Coding is the most sensitive subcomponent... 3. qEEG data was consistent with prior clinical evidence.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8edf43eb-9da6-423d-9b92-d9867d0a56cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.03,
        "y": 0.0016
      },
      "kind": "paragraph",
      "text": "Background: Cognitive function was assessed in 31 patients with CIAS across four RL-007 cohorts (10, 20, 40 & 80mg). The primary objectives were to confirm safety and identify signals of cognitive benefit.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7631d61-dc56-4133-8ab2-1ce7e47a4cec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "title",
      "text": "atai's Phase 2a study in CIAS demonstrated positive cognitive signals on a subset of MCCB neurocognitive endpoints",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3e42828-2c03-4237-b576-484c4b42eb42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Evidence: Efficacy Signals Reproduced in Phase 2a Study in CIAS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "142f98a6-43db-4572-837d-b7f6ca29adea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "722001cb-f32a-4ada-bc7f-1757bb9e9ced",
      "evidence": "The slide presents a clear narrative arc, starting with background information, then highlighting the study's objectives, results, and conclusions, which follows a typical data story arc.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "ca4dd150-5a74-4a60-9af2-22ea71358ce8",
      "evidence": "Presents clinical trial data alongside specific efficacy metrics (Cohen's d) to support a therapeutic claim.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}